Technical Analysis for CU6 - Clarity Pharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 1.49% | |
| NR7 | Range Contraction | 1.49% | |
| Narrow Range Bar | Range Contraction | 1.49% | |
| Inside Day | Range Contraction | 1.49% | |
| Fell Below 50 DMA | Bearish | 1.49% | |
| MACD Bearish Centerline Cross | Bearish | 1.49% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | 1 day ago |
| 20 DMA Resistance | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Up 3% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.06 |
| 52 Week Low | 0.675 |
| Average Volume | 550,362 |
| 200-Day Moving Average | 1.664 |
| 50-Day Moving Average | 2.720 |
| 20-Day Moving Average | 2.755 |
| 10-Day Moving Average | 2.726 |
| Average True Range | 0.116 |
| RSI (14) | 50.50 |
| ADX | 14.72 |
| +DI | 24.412 |
| -DI | 21.846 |
| Chandelier Exit (Long, 3 ATRs) | 2.714 |
| Chandelier Exit (Short, 3 ATRs) | 2.947 |
| Upper Bollinger Bands | 2.934 |
| Lower Bollinger Band | 2.576 |
| Percent B (%b) | 0.43 |
| BandWidth | 13.002 |
| MACD Line | -0.002 |
| MACD Signal Line | 0.011 |
| MACD Histogram | -0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.880 | ||||
| Resistance 3 (R3) | 2.887 | 2.843 | 2.855 | ||
| Resistance 2 (R2) | 2.843 | 2.805 | 2.840 | 2.847 | |
| Resistance 1 (R1) | 2.787 | 2.782 | 2.765 | 2.780 | 2.838 |
| Pivot Point | 2.743 | 2.743 | 2.733 | 2.740 | 2.743 |
| Support 1 (S1) | 2.687 | 2.705 | 2.665 | 2.680 | 2.622 |
| Support 2 (S2) | 2.643 | 2.682 | 2.640 | 2.613 | |
| Support 3 (S3) | 2.587 | 2.643 | 2.605 | ||
| Support 4 (S4) | 2.580 |
